Mediaplanet and Former NFL Player Brandon Marshall Team Up for Men s Health prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Interventions to reduce fear of cancer recurrence could be cost effective and improve patients quality of life. (
Psycho-Oncology)
A novel cancer vaccine tailored to a patient s specific tumor stimulated an immune response in its first clinical test, a patient with advanced pancreatic cancer. (
Washington University in St. Louis)
Janssen and Johnson & Johnson announced they will not pursue regulatory approval of the combination of apalutamide (Erleada) and abiraterone (Zytiga) plus prednisone for metastatic castration-resistant prostate cancer after evaluating results of the phase III ACIS trial.
Almost half of patients with previously treated genetically defined acute leukemias responded to the oral menin inhibitor SNDX-5613 in a phase I trial, Syndax announced.
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels ( 50 ng/dL) through 48 weeks in the Phase 3 HERO study
Conference call and webcast to be held on December 21 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug Administration (FDA) has approved ORGOVYX™ (relugolix) for the treatment of adult patients with advanced prostate cancer. ORGOVYX, which was granted Priority Review by the FDA, is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for men with advanced prostate cancer. The approval is based on efficacy and safety data from
Sumitovant Biopharma Announces Myovant Sciences receives FDA Approval of ORGOVYXTM (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Home / Top News / Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels ( 50 ng/dL) through 48 weeks in the Phase 3 HERO study
Conference call and webcast to be held on December 21 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug Administration (FDA) has approved ORGOVYX™ (relugolix) for the treatment of adult patients with advanced prostate cancer. ORGOVYX, which was granted Priority Re